UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicinalProductDefinition SimvastatinBluefish-20mg-Tablet-SE-BS-MPD
identifier: http://ema.europa.eu/fhir/mpId
/SE-100002566-00026678, http://ema.europa.eu/fhir/eurdId
/2709
domain: Human use
status: Current
combinedPharmaceuticalDoseForm: Film-coated tablet
indication:
Hypercholesterolaemia Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (such as exercise, weight reduction) is inadequate. Treatment of homozygous familial hypercholesterolaemia (HoFH) as an adjunct to diet and other lipid-lowering treatments (e.g. LDL-apheresis) or if such treatments are not appropriate. Cardiovascular prevention Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 5.1).
legalStatusOfSupply: Medicinal product subject to medical prescription
classification: simvastatin
name
productName: Simvastatin Bluefish 20 mg filmdragerad tablett
part
part: SimvastatinBluefish
type: Scientific name part
part
part: 20 mg
type: Strength part
part
part: Filmdragerad tablett
type: Pharmaceutical dose form part
Usages
Country Language Kingdom of Sweden Swedish